Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

BRAF inhibition in hairy cell leukemia with low-dose vemurafenib

Blood (2016) 127 (23): 2847–2855.

https://doi.org/10.1182/blood-2015-11-680074

Published: 2016

Includes: Supplemental data

Journal Articles

BRAF Inhibition in Hairy Cell Leukemia: Multicentre Experience of 21 Patients Treated with Vemurafenib

Dietrich Sascha, MD, Andreas Pircher, MD, Mindaugas Andrulis, MD, Elena Ellert, MD, Frédéric Peyrade, Clemens-Martin Wendtner, MD, George A Follows, Martin JS Dyer, Thomas Elter, MD, Robert Zeiser, Anita Gaehler, MD, Michael Herrmann, Michael Herold, MDPhD, Claire Dearden, MD, Hanno Glimm, MD, Michael Hallek, MD, Anthony D Ho, MD, Michael Steurer, Thorsten Zenz, MD

Blood (2014) 124 (21): 3634.

https://doi.org/10.1182/blood.V124.21.3634.3634

Published: 2014

Journal Articles

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia

Blood (2014) 124 (1): 49–62.

https://doi.org/10.1182/blood-2014-02-556399

Published: 2014

Includes: Supplemental data

Journal Articles

The Use of Chemoimmunotherapy Improves the Outcome of Patients with Chronic Lymphocytic Leukaemia (CLL) – a Metaanalysis of Five Trials of the German CLL Study Group (GCLLSG)

Paula Cramer, MD, Susanne Isfort, MD, Jasmin Bahlo, Raymonde Busch, Petra Langerbeins, MD, Anna-Maria Fink, MD, Valentin Goede, MD, Thomas Elter, MD, Manuela A. Bergmann, MD, Martina Beate Stauch, MD, Stephan Stilgenbauer, MD, Clemens-Martin Wendtner, MD, Kirsten Fischer, MD, Michael Hallek, MD PhD, Barbara F. Eichhorst, MD

Blood (2012) 120 (21): 3936.

https://doi.org/10.1182/blood.V120.21.3936.3936

Published: 2012

Journal Articles

Elimination of Established Risk-Factors in Primary Central Nervous System Lymphoma - Impact of High-Dose Chemotherapy Followed by Autologous Stem-Cell Transplantaion - a Multicenter Retrospective Analysis

Elisabeth Schorb, MD, Benjamin Kasenda, MD, Johannes Atta, Nikolas von Bubnoff, MD, Thomas Elter, MD, Georg Hess, Stefan W. Krause, MD, Anke Morgner, Kaun Stephan, Kristina Fritsch, MD, Jürgen Finke, MD, Gerald Illerhaus

Blood (2011) 118 (21): 3089.

https://doi.org/10.1182/blood.V118.21.3089.3089

Published: 2011

Journal Articles

Proposal of A Prognostic Score for Previously Untreated Patients with Chronic Lymphocytic Leukemia Based on An Overall Survival Analysis of Three German CLL Study Group Phase III Trials

Jasmin Bahlo, Natali Pflug, MD, Thomas Elter, MD, Kathrin Bauer, MD, Barbara Eichhorst, MD, Manuela Bergmann, MD, Raymonde Busch, Hartmut Döhner, MD, Stephan Stilgenbauer, MD, Clemens-Martin Wendtner, MD, Kirsten Fischer, MD, Michael Hallek, MD

Blood (2011) 118 (21): 2831.

https://doi.org/10.1182/blood.V118.21.2831.2831

Published: 2011

Journal Articles

Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis

Barbara F. Eichhorst, Kirsten Fischer, Anna-Maria Fink, Thomas Elter, Clemens M. Wendtner, Valentin Goede, Manuela Bergmann, Stephan Stilgenbauer, Georg Hopfinger, Matthias Ritgen, Jasmin Bahlo, Raymonde Busch, Michael Hallek, for the German CLL Study Group (GCLLSG)

Blood (2011) 117 (6): 1817–1821.

https://doi.org/10.1182/blood-2010-04-282228

Published: 2011

Includes: Supplemental data

Journal Articles

Rituximab for Patients with Chronic Lymphocytic Leukemia: A Systematic Review

Kathrin Bauer, MD, Olaf Weingart, MD, Ina Monsef, Skoetz Nicole, MD, Thomas Elter, MD, Michael Hallek, MD, Andreas Engert, MD

Blood (2010) 116 (21): 4632.

https://doi.org/10.1182/blood.V116.21.4632.4632

Published: 2010

Journal Articles

Overall Survival Advantage and Acceptable Safety Profile with Fludarabine In Combination with Alemtuzumab (FluCam) In Previously Treated Patients with Advanced Stage Chronic Lymphocytic Leukemia

Andreas Engert, MD, Liana Gercheva, MD, PhD, Galina Pilipenko, MD, Tadeusz Robak, MD, PhD, Jingyang Wu, MS, Cynthia A. Sirard, MD, Thomas Elter, MD

Blood (2010) 116 (21): 919.

https://doi.org/10.1182/blood.V116.21.919.919

Published: 2010

Journal Articles

Chemoimmuno-Therapy with Fludarabine, Cyclophosphamide and Alemtuzumab (FC-Cam) in Patients with Relapsed or Genetic High-Risk CLL: Final Analysis of the CLL2L Trial of the German CLL Study Group.

Thomas Elter, MD, Rojin James, Stephan Stilgenbauer, MD, Sebastian Boettcher, MD, Matthias Ritgen, MD, Hartmut Doehner, MD, Michael Hallek, MD, Andreas Engert, MD

Blood (2009) 114 (22): 209.

https://doi.org/10.1182/blood.V114.22.209.209

Published: 2009

Journal Articles

Improved Progression-Free Survival (PFS) of Alemtuzumab (Campath®, MabCampath®) Plus Fludarabine (Fludara®) Versus Fludarabine Alone as Second-Line Treatment of Patients with B-Cell Chronic Lymphocytic Leukemia: Preliminary Results From a Phase III Randomized Trial.

Andreas Engert, MD, Liana Gercheva, MD, Tadeusz Robak, Pilipenko Galina, Jingyang Wu, MS, Cynthia A. Sirard, MD, Thomas Elter, MD

Blood (2009) 114 (22): 537.

https://doi.org/10.1182/blood.V114.22.537.537

Published: 2009

Journal Articles

Final Results of a Phase Ib Trial of Atacicept to Neutralize APRIL and BLyS in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia (CLL).

David M Kofler, MD, Barbara B Gawlik, MD, Thomas Elter, MD, Athos Gianella-Borradori, MD, Clemens M Wendtner, MD, Michael Hallek, MD

Blood (2009) 114 (22): 2373.

https://doi.org/10.1182/blood.V114.22.2373.2373

Published: 2009

Journal Articles

The Performance of Computed Tomography (CT) Scans or Ultrasound Has No Clinical Relevance in Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Metaanalysis from Three Phase III Studies of the German CLL Study Group (GCLLSG).

Barbara F. Eichhorst, MD, Kirsten Fischer, MD, Anna- Maria Fink, MD, Thomas Elter, MD, Clemens M Wendtner, MD, Raymonde Busch, Dipl., math., Michael Hallek, German CLL Study Group

Blood (2008) 112 (11): 1053.

https://doi.org/10.1182/blood.V112.11.1053.1053

Published: 2008

Journal Articles

Chemoimmuno-Therapy with Fludarabine, Cyclophosphamide and Alemtuzumab in Patients with Relapsed/Refractory CLL: Interim Analysis of the CLL2L Trial of the German CLL Study Group

Thomas Elter, MD, Rojin James, Stephan Stilgenbauer, MD, PhD, Matthias Ritgen, Michael Hallek, M.D., Andreas Engert

Blood (2008) 112 (11): 3170.

https://doi.org/10.1182/blood.V112.11.3170.3170

Published: 2008

Journal Articles

Physical Exercise Is Possible in Patients with Critical Cytopenia Undergoing High- Dose Chemotherapy for Acute Leukaemia or Aggressive Lymphoma

Thomas Elter, MD, Freerk Baumann, Martina Stipanov, Eva Heuser, Michael S von Bergwelt-Baildon, Wilhelm Bloch, MD, Michael Hallek

Blood (2008) 112 (11): 4719.

https://doi.org/10.1182/blood.V112.11.4719.4719

Published: 2008

Journal Articles

Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)

Holger Schulz, Ute Rehwald, Franck Morschhauser, Thomas Elter, Christoph Driessen, Thomas Rüdiger, Peter Borchmann, Roland Schnell, Volker Diehl, Andreas Engert, Marcel Reiser

Blood (2008) 111 (1): 109–111.

https://doi.org/10.1182/blood-2007-03-078725

Published: 2008

Includes: Supplemental data

Journal Articles

FluCam—a New, 4-Weekly Combination of Fludarabine and Alemtuzumab for Patients with Relapsed Chronic Lymphocytic Leukemia.

Thomas Elter, P. Bochmann, H. Schulz, M. Reiser, S. Trelle, P. Staib, T. Schinkothe, M. Hallek, Andreas Engert

Blood (2004) 104 (11): 2517.

https://doi.org/10.1182/blood.V104.11.2517.2517

Published: 2004

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

BRAF inhibition in hairy cell leukemia with low-dose vemurafenib

BRAF Inhibition in Hairy Cell Leukemia: Multicentre Experience of 21 Patients Treated with Vemurafenib

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia

The Use of Chemoimmunotherapy Improves the Outcome of Patients with Chronic Lymphocytic Leukaemia (CLL) – a Metaanalysis of Five Trials of the German CLL Study Group (GCLLSG)

Elimination of Established Risk-Factors in Primary Central Nervous System Lymphoma - Impact of High-Dose Chemotherapy Followed by Autologous Stem-Cell Transplantaion - a Multicenter Retrospective Analysis

Proposal of A Prognostic Score for Previously Untreated Patients with Chronic Lymphocytic Leukemia Based on An Overall Survival Analysis of Three German CLL Study Group Phase III Trials

Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis

Rituximab for Patients with Chronic Lymphocytic Leukemia: A Systematic Review

Overall Survival Advantage and Acceptable Safety Profile with Fludarabine In Combination with Alemtuzumab (FluCam) In Previously Treated Patients with Advanced Stage Chronic Lymphocytic Leukemia

Chemoimmuno-Therapy with Fludarabine, Cyclophosphamide and Alemtuzumab (FC-Cam) in Patients with Relapsed or Genetic High-Risk CLL: Final Analysis of the CLL2L Trial of the German CLL Study Group.

Improved Progression-Free Survival (PFS) of Alemtuzumab (Campath®, MabCampath®) Plus Fludarabine (Fludara®) Versus Fludarabine Alone as Second-Line Treatment of Patients with B-Cell Chronic Lymphocytic Leukemia: Preliminary Results From a Phase III Randomized Trial.

Final Results of a Phase Ib Trial of Atacicept to Neutralize APRIL and BLyS in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia (CLL).

The Performance of Computed Tomography (CT) Scans or Ultrasound Has No Clinical Relevance in Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Metaanalysis from Three Phase III Studies of the German CLL Study Group (GCLLSG).

Chemoimmuno-Therapy with Fludarabine, Cyclophosphamide and Alemtuzumab in Patients with Relapsed/Refractory CLL: Interim Analysis of the CLL2L Trial of the German CLL Study Group

Physical Exercise Is Possible in Patients with Critical Cytopenia Undergoing High- Dose Chemotherapy for Acute Leukaemia or Aggressive Lymphoma

Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)

FluCam—a New, 4-Weekly Combination of Fludarabine and Alemtuzumab for Patients with Relapsed Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only